Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation
Status:
Recruiting
Trial end date:
2023-05-02
Target enrollment:
Participant gender:
Summary
This study will be a multicenter Phase IIIb open-label, three-cohort study of asciminib in
patients with CML-CP without T315I mutation who have had at least 2 prior TKIs and CML-CP
harboring the T315I mutation with at least 1 prior TKI